Tuberculosis (TB)

Tuberculosis — scientific infographic poster
tuberculosis granuloma formation

What Tuberculosis Is

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can spread to other parts of the body, such as the kidneys, spine, and brain. Tuberculosis can be latent or active, with active tuberculosis being contagious and requiring treatment.

How Common Tuberculosis Is Worldwide

The World Health Organization (WHO) estimates that 10.7 million people fell ill with tuberculosis in 2024 (5.8 million men, 3.7 million women and 1.2 million children) and that 1.23 million people died of it, including 150,000 people with HIV. WHO describes tuberculosis as the world’s leading cause of death from a single infectious agent. About a quarter of the world’s population is estimated to have been infected with tuberculosis bacteria; people with this silent infection do not feel sick and are not contagious, and about 5–10% of them eventually develop tuberculosis disease (WHO fact sheet; Houben and Dodd 2016).

Types of Tuberculosis

1. Latent Tuberculosis

2. Active Tuberculosis

Symptoms of Active Tuberculosis

Common symptoms include:

Causes and Transmission

Risk Factors

Diagnosis

Treatment Options

Drug-Resistant Tuberculosis

Drug-resistant tuberculosis occurs when the bacteria do not respond to the standard treatment due to resistance to certain medications.

1. Multidrug-Resistant TB (MDR-TB)

2. Extensively Drug-Resistant TB (XDR-TB)

3. Pre-Extensively Drug-Resistant TB (Pre-XDR-TB)

The 6-Month All-Oral Regimen

The TB-PRACTECAL trial (Belarus, South Africa and Uzbekistan, people aged 15 and over) compared a 24-week all-oral regimen of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) with a 9-to-20-month standard regimen for rifampin-resistant lung tuberculosis. In the main analysis, 11% of the BPaLM group and 48% of the standard-care group had an unfavourable outcome (death, treatment failure, stopping treatment, loss to follow-up or relapse). Serious or grade 3 and higher side effects occurred in 19% vs 59%. Recruitment was stopped early (Nyang’wa 2022). WHO reports that its 2022 guidelines prioritized this 6-month regimen (BPaLM/BPaL) as a treatment of choice, and that about 34,000 people with multidrug- or rifampicin-resistant tuberculosis started 6-month regimens in 2024, up from 5,653 in 2023 and 1,744 in 2022. WHO also reports that only about 2 in 5 people with multidrug-resistant tuberculosis accessed treatment in 2024.

Prevention Strategies

Complications of Tuberculosis

Key Research Papers

Historical Background

Robert Koch identified Mycobacterium tuberculosis as the causative agent of tuberculosis on March 24, 1882, a discovery for which he received the 1905 Nobel Prize in Physiology or Medicine. The introduction of streptomycin in 1944 by Albert Schatz, Elizabeth Bugie, and Selman Waksman marked the beginning of effective antibiotic treatment for tuberculosis.

Key Research Papers

Every citation below has been re-checked against the PubMed record. An earlier version of this list attached a DOI to each entry, and those DOIs were shuffled — each one resolved to a real paper, but not the one it was labelled as. The most striking mismatch: the Conradie drug-resistant tuberculosis trial linked to a placebo-controlled trial of bezafibrate in primary biliary cholangitis. Links are now numeric PubMed IDs.

  1. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nature Reviews Disease Primers. 2016;2:16076. — PubMed PMID: 27784885
  2. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. New England Journal of Medicine. 2013;368(8):745-755. — PubMed PMID: 23425167
  3. Lawn SD, Zumla AI. Tuberculosis. The Lancet. 2011;378(9785):57-72. — PubMed PMID: 21420161
  4. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New England Journal of Medicine. 2021;384(18):1705-1718. The trial behind the four-month regimen now offered as an alternative to six months. — PubMed PMID: 33951360
  5. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. New England Journal of Medicine. 2011;365(23):2155-2166. The basis of the 12-dose weekly regimen for latent infection. — PubMed PMID: 22150035
  6. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine. 2014;371(8):723-732. — PubMed PMID: 25140958
  7. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. New England Journal of Medicine. 2020;382(10):893-902. The Nix-TB trial of bedaquiline, pretomanid and linezolid. — PubMed PMID: 32130813
  8. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010;363(11):1005-1015. The Xpert MTB/RIF validation study. — PubMed PMID: 20825313
  9. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet. 2006;368(9547):1575-1580. — PubMed PMID: 17084757
  10. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Medicine. 2016;13(10):e1002152. The source of the widely quoted “one quarter of the world” figure. — PubMed PMID: 27780211
  11. Horsburgh CR Jr, Barry CE 3rd, Lange C. Treatment of tuberculosis. New England Journal of Medicine. 2015;373(22):2149-2160. Added: the paper whose DOI was previously attached to the Pai citation. — PubMed PMID: 26605929
  12. Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. New England Journal of Medicine. 2022;386(10):911-922. The SHINE trial. — PubMed PMID: 35263517
  13. Nyang'wa BT, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. New England Journal of Medicine. 2022;387(25):2331-2343. The TB-PRACTECAL trial. — PubMed PMID: 36546625
  14. Viney K, Linh NN, Gegia M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. European Respiratory Journal. 2021;57(4):2100361. — PubMed PMID: 33833074
  15. World Health Organization. Tuberculosis: key facts (fact sheet, updated 4 March 2026). Source of the 2024 burden figures, the BCG vaccine statement and the 6-month regimen figures. — WHO fact sheet
  16. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment — drug-resistant tuberculosis treatment. Geneva: WHO. — WHO guideline An earlier version of this page cited these guidelines as an article in The Lancet Infectious Diseases 2019;19(11):e348-e364. WHO guidelines are published by WHO, not in that journal; the reference has been pointed at the source document.

PubMed Topic Searches

The following PubMed topic searches retrieve current peer-reviewed literature on Tuberculosis. Each link opens a live PubMed query so you always see the most recent publications.

  1. PubMed: Tuberculosis review
  2. PubMed: Mycobacterium tuberculosis pathogenesis
  3. PubMed: Multidrug resistant tuberculosis MDR-TB
  4. PubMed: Bedaquiline tuberculosis treatment
  5. PubMed: Isoniazid rifampin tuberculosis
  6. PubMed: Latent tuberculosis infection treatment
  7. PubMed: BCG vaccine tuberculosis efficacy
  8. PubMed: Tuberculosis HIV coinfection
  9. PubMed: GeneXpert tuberculosis diagnosis
  10. PubMed: WHO tuberculosis global report
  11. PubMed: Extrapulmonary tuberculosis
  12. PubMed: Vitamin D tuberculosis

Back to Table of Contents

Connections

Back to Table of Contents